Ayman AlAbdallah is a partner at Mubadala Ventures, the San Francisco-based venture capital arm of Mubadala Capital. He is focused on investing in transformative healthcare technology, biotechnology, and deeptech companies. Within biotechnology, Ayman’s domain expertise centers on the convergence of AI and drug discovery and development, where he partners with companies from their formation through growth and public rounds. Companies he has backed include Exscientia (EXAI), Neumora (NMRA), Recursion (RXRX), Vir Biotechnology (VIR), and Vividion (acquired by Bayer), among others. He currently serves as a director or observer on the boards of numerous emerging biotechnology companies, including Iambic AI, Juvena Therapeutics, Unlearn AI, Vevo Therapeutics, and Xilis. Ayman joined Mubadala Capital in 2018 as part of the initial team launching the firm’s venture capital business in San Francisco. Prior to Mubadala Capital, his career spanned corporate development and M&A (Tecan Group; SWX: Tecan), management consulting (Accenture), and hedge fund investing (OMERS Capital). He has deep operational expertise with several startups, including Sentinelle Medical (acquired by Hologic), Pullsar Technologies (acquired by Tecan), Airo Health (Y Combinator, Summer 2016 batch), and Xilis (President, 2023). Ayman completed his M.B.A. and mechanical engineering studies at the University of Toronto, where he received the Chalmers Award and a fellowship for his engineering research thesis investigating novel Lab-on-a-Chip platforms.